CVT-510: A Selective A1 Adenosine Receptor Agonist

Cardiovascular Drug Reviews

Volumn 21, Issue 4, 2003, Pages 277-292

  Cheung, Jim W ^a   Lerman, Bruce B ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Adenosine; Adenosine receptors; Antiarrhythmics; Arrhythmia; Cardiovascular diseases; CVT 510 ; Tachycardia, supraventricular

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CVT 2759; DILTIAZEM; ISOPRENALINE; LIGAND; N(G) METHYLARGININE; NUCLEOSIDE; RADIOLIGAND; RECEPTOR SUBTYPE; TECADENOSON; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR CONDUCTION; BRONCHOSPASM; BURNING SENSATION; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CHRONOTROPISM; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DROMOTROPIC ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DYSPNEA; ELECTROPHYSIOLOGY; FLUSHING; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROTECTION; HEART RATE; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INFLAMMATORY CELL; KIDNEY; LIGAND BINDING; LIPOLYSIS; NERVE STIMULATION; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SECOND MESSENGER; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SUPRAVENTRICULAR PREMATURE BEAT; THORAX PAIN; THROMBOCYTE AGGREGATION; VERTIGO;

EID: 0346158489     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00122.x     Document Type: Review

References (70)

1. Abebe W, Hussain T, Olanreqaju H, Mustafa SI. Role of nitric oxide in adenosine receptor-mediated relaxation of porcine coronary artery. Am J Physiol 1995;269:H1672-H1678.
2. Belardinelli L, Giles WR, West A. Ionic mechanisms of adenosine actions in pacemaker cells from the rabbit heart. J Physiol 1988;405:615-633.
3. Belardinelli L, Isenberg G. Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. Am J Physiol 1983;244:H734-H737.
4. Belardinelli L, Wu S-N, Visentin S. Adenosine regulation of cardiac electrical activity. In: Zipes DP, Jalife J, Eds. Cardiac electrophysiology: From cell to bedside. Philadelphia: WB Saunders Co, 1990; 344-353.
5. Belardinelli L, Shryrock JC, Song Y, Wang D, Srinivas M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 1995;9:359-365.
6. Biaggioni I, Onrot J, Hollister A, Robertson D. Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole. Life Sci 1986;39:2229-2236.
7. Biaggioni I, Killian TJ, Mosqueda-Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation 1991;83:1668-1675.
8. 1 adenosine receptors in atrial and ventricular myocardium from disease human hearts. Circ Res 1989;65:1201-1211.
9. + channels. Am J Physiol 1994;267:H1455-H1460.
10. Crea F, Pupita G, Galassi AR, et al. Role of adenosine in pathogenesis of anginal pain. Circulation 1990;81:164-172.
11. 1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369-385.
12. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycarida: Dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990;113:104-10.
13. DiMarco JP. Adenosine and digoxin. In: Zipes DP, Jalife J, Eds. Cardiac electrophysiology: From cell to bedside. Philadelphia: WB Saunders Co, 1990;933-938.
14. Drury AN, Szent-Geörgyi A. The physiological activity of adenine compounds with especial reference to their action on the mammalian heart. J Physiol 1929;68:213-237.
15. Ellenbogen K and the TEMPEST Study Group from the Medical College of Virginia, Richmond. A randomized, double-blind, placebo-controlled study of intravenous Tecadenoson in patients with PSVT undergoing an electrophysiologic study: Trial to Evaluate the Management of PSVT during Electrophysiologic Study with Tecadenoson (TEMPEST). Circulation 2002;106:2986A (Abstract).
16. Ellenbogen K. TEMPEST (Trial to Evaluate the Management of PSVT [Paroxysmal Supraventricular Tachycardia] during Electrophysiology). Clin Cardiol 2003;26:100-101 (Abstract).
17. Faure M, Voyno-Yasenetskaya TA, and Bourne HR. cAMP and beta gamma subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. J Biol Chem 1994;269:7851.
18. 2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995;96:1979-1986.
19. 1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J Pharmacol Exp Ther 2003;305:225-231.
20. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K, Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-557.
21. Gao Z, Rosete J, Kohler G, Huang B-L, Blackburn B, Belardinelli L. Negative chronotropic effect of CVT-510 in anesthesized and awake rats. Drug Dev Res 2001;52:424-430.
22. Gauda EB, Northington FJ, Linden J, Rosin DL. Differential expression of a(2a), A(1)-adenosine and D(2)-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. Brain Res 2000;872:1-10.
23. Haynes J, Obiako B, Thompson WJ, Downey J. Adenosine-induced vasodilation: Receptor characterization in pulmonary circulation. Am J Physiol 1995;268:H1872-H1868.
24. Hein TW, Wang W, Zoghi B, Muthuchamy M, Kuo L. Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine. J Mol Cell Cardiol 2001; 33:271-282.
25. Hood MA, Smith WM. Adenosine versus verapamil in the treatment of supraventricular tachycardia: A randomized double-crossover trial. Am Heart J 1993;125:1543-1549.
26. Iwai S, Markowitz SM, Stein K et al. Response to adenosine differentiates focal from macroreentrant atrial tachycardia. Circulation 2002;106:2793-2799.
27. 2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun 1994;199:905-910.
28. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280:301-309.
29. 1 adenosine receptors. Biochem Biophys Res Commun 1986;140:406-413.
30. + channels by adenosine in isolated atrial cells: Involvement of GTP-binding proteins. Pflüger's Arch 1986;407:264-274.
31. Lerman BB, Belardinell L, West GA, Berne RM, Dimarco JP. Adenosine-sensitive ventricular tachycardia: Evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986;74:270-280.
32. Lerman BB, Greenberg M, Overhold ED, et al. Differential electrophysiological properties of decremental retrograde pathways in short RP' tachycardia. Circulation 1987;76:21-31.
33. Lerman BB, Wesley RC, DiMarco JP, Haines DE, Berlardinelli L. Antiadrenergic effects of adenosine on His-Purkinje automaticity: Evidence for accentuated antagonism. J Clin Invest 1988;82:2127-2135.
34. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine: Basic and clinical concepts. Circulation 1991;83:1499-1509.
35. Lerman BB, Stein KM, Markowitz SM. Idiopathic right ventricular tachycardia: A clinical approach. Pacing Clin Electrophysiol 1996;12:2120-2137.
36. 1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Therapeut 2001;6:237-245.
37. Linden J, Thai T, Figler H, Jin X, Robeva AS. Characterization of human A(2B) adenosine receptors: Radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 1999;56:705-713.
38. Mittal S, Stein KM, Markowitz SM, Slotwiner DJ, Rohatgi S, Lerman BB. Induction of neurally mediated syncope with adenosine. Circulation 1999;99:1318-1324.
39. 1 receptor blockade on glomerular hemodynamics: Involvement of renin-angiotensin system. Am J Physiol 1994;267:F504-F510.
40. o. J Biol Chem 1991;266:22285-22289.
41. 1 adenosine receptor agonist, is associated with fewer arrhythmias than adenosine. Circulation 2001;104:2317A (Abstract).
42. Nunain, SO, Garrat C, Paul V, Debbas N, Ward DE, Camm AJ. Effect of intravenous adenosine on human atrial and ventricular repolarisation. Cardiovasc Res 1992;26:939-943.
43. 3 adenosine receptor. J Biol Chem 1995;270:16895-16902.
44. Parsons M, Young L, Lee JE, Jacobson KA, Liang BT. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J 2000;14:1423-1431.
45. Polosa R. Adenosine-receptor subtypes: Their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J 2002;20:488-496.
46. 1-adenosine receptor agonist. J Am Coll Cardiol 2003;42: 1098-1102.
47. Ramkumar V, Nie Z, Rybak LP, Maggiwar SB. Adenosine, antioxidant enzymes, and cytoprotection. Trends Pharmacol Sci 1995;16:283-285.
48. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-16890.
49. Ribeiro JA, Sebastio AM, de Mendonca A. Adenosine receptors in the nervous system: Pathophysiological implications. Progr Neurobiol 2003;68:377-392.
50. 2b adenosine receptor. Mol Endocrinol 1992;6: 1598-1604.
51. 1 adenosine receptor. J Biol Chem 1999;274:3617-3721.
52. 2A receptors in the rat central nervous system. J Comp Neurol 1998;401:163-186.
53. 3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-10369.
54. Shen WK, Hammill SC, Munger TM, et al. Adenosine: Potential modulator for vasovagal syncope. J Am Coll Cardiol 1996;28:146-154.
55. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology and pharmacology. Am J Cardiol 1997;79(12A):2-10.
56. Slotwiner DJ, Lerman, BB. Adenosine and cardiac arrhythmias. In: Burnstock G, Dobson JG, Liang BT, Linden J, eds. Cardiovascular biology of purines. Norwell: Kluwer Academic Publishers Group, 1998;126-142.
57. 1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Br J Pharmacol 1999; 126:137-146.
58. 2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem 1995;270:2387-2394.
59. 2A adenosine receptors in HEK-293 cells. Biochem J 2000;352(pt 1):203-210.
60. 2 receptors: Structure-function relationships. Med Res Rev 1992;12:423-471.
61. 2A adenosine receptors and their function in human platelets. Circulation 1999;99:2499-2502.
62. 3 receptor expression and function in eosinophils. Am J Resp Cell Mol Biol 1997;16:531-537.
63. F) in single rabbit atrioventricular nodal myocytes. FASEB J 1984;8:A611 (Abstract).
64. Wilbur SL, Marchlinski FE. Adenosine as an antiarrhythmic agent. Am J Cardiol 1997;79(12A): 30-37.
65. 1 receptor antagonist. J Am Soc Nephrol 1999;10:714-720.
66. 1-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am J Physiol Heart Circ Physiol 1991; 280:H334-H343.
67. Zannikos PN, Rohatagi S, Jensen BK. Pharmokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers. J Clin Pharmacol 2001;41:61-69.
68. F) by adenosine in rabbit sino-atrial myocytes. J Physiol 1994;475P (Abstract).
69. Zaza A. CVT-510 CV Therapeutics. Curr Opin Invest Drugs 2002;3:96-100.
70. Zima A, Martynyuk AE, Seubert CN et al. Antagonism of the positive dromotropic effect of isoproterenol by adenosine: Role of nitric oxide, cGMP-dependent cAMP-phosphodiesterase and protein kinase G. J Mol Cell Cardiol 2000;32:1609-1619.